3β-hydroxysteroid dehydrogenase is a possible pharmacological target in the treatment of castration-resistant prostate cancer

Endocrinology

Volumn 151, Issue 8, 2010, Pages 3514-3520

  Evaul, Kristen ^a   Li, Rui ^a   Papari Zareei, Mahboubeh ^a   Auchus, Richard J ^a   Sharifi, Nima ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE; ANDROGEN RECEPTOR; ANDROSTENEDIOL; ANDROSTENEDIONE; FK 506 BINDING PROTEIN; FK 506 BINDING PROTEIN 5; MESSENGER RNA; PRASTERONE; PROSTATE SPECIFIC ANTIGEN; SERINE PROTEINASE; TESTOSTERONE; UNCLASSIFIED DRUG; 3 (OR 17) BETA HYDROXYSTEROID DEHYDROGENASE; 3 (OR 17)-BETA-HYDROXYSTEROID DEHYDROGENASE; ANDROSTANOLONE; ANTINEOPLASTIC AGENT; AR PROTEIN, HUMAN; DRUG DERIVATIVE; ENZYME INHIBITOR; HYDROXYSTEROID DEHYDROGENASE; TRILOSTANE;

ARTICLE; CANCER RESISTANCE; CASTRATION; CELL LINE; CHROMATIN; CONTROLLED STUDY; DEHYDROGENATION; DRUG TARGETING; ENHANCER REGION; GENETIC TRANSCRIPTION; HORMONE METABOLISM; PRIORITY JOURNAL; PROSTATE CANCER; RECEPTOR OCCUPANCY; BIOLOGICAL MODEL; CARCINOMA; CELL NUCLEUS; DOSE RESPONSE; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG SCREENING; GENETICS; HUMAN; MALE; METABOLISM; ORCHIECTOMY; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; TREATMENT FAILURE; TUMOR CELL LINE;

17-HYDROXYSTEROID DEHYDROGENASES; ANTINEOPLASTIC AGENTS; CARCINOMA; CELL LINE, TUMOR; CELL NUCLEUS; DEHYDROEPIANDROSTERONE; DIHYDROTESTOSTERONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; HUMANS; MALE; MODELS, BIOLOGICAL; ORCHIECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TREATMENT FAILURE;

EID: 77954909020     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2010-0138     Document Type: Article

References (20)

1. Sharifi N, Gulley JL, Dahut WL 2005 Androgen deprivation therapy for prostate cancer. JAMA 294:238-244 (Pubitemid 41043794)
2. Scher HI, Sawyers CL 2005 Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgenreceptor signaling axis. J Clin Oncol 23:8253-8261
3. McPhaul MJ 2008 Mechanisms of prostate cancer progression to androgen independence. Best Pract Res Clin Endocrinol Metab 22: 373-388 (Pubitemid 351611961)
4. Yuan X, Balk SP 2009 Mechanisms mediating androgen receptor reactivation after castration. Urol Oncol 27:36-41
5. Sharifi N 2009 Hormonal therapy for prostate cancer: toward further unraveling of androgen receptor function. Anticancer Agents Med Chem 105:913-916
6. Page ST, Lin DW, Mostaghel EA, Hess DL, True LD, Amory JK, Nelson PS, Matsumoto AM, Bremner WJ 2006 Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab 91:3850-3856
7. Mostaghel EA, Page ST, Lin DW, Fazli L, Coleman IM, True LD, Knudsen B, Hess DL, Nelson CC, Matsumoto AM, Bremner WJ, Gleave ME, Nelson PS 2007 Intraprostatic androgens and androgen- regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res 67:5033-5041
8. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD, Nelson PS 2008 Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration- resistant tumor growth. Cancer Res 68:4447-4454
9. Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL 2005 Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 11:4653-4657
10. Ghayee HK, Auchus RJ 2007 Basic concepts and recent developments in human steroid hormone biosynthesis. Rev Endocr Metab Disord 8:289-300
11. Simard J, Ricketts ML, Gingras S, Soucy P, Feltus FA, Melner MH 2005 Molecular biology of the 3β-hydroxysteroid dehydrogenase/ delta5-δ4 isomerase gene family. Endocr Rev 26:525-582
12. Lorence MC, Murry BA, Trant JM, Mason JI 1990 Human 3 β-hydroxysteroid dehydrogenase/delta 5-delta4 isomerase from placenta: expression in nonsteroidogenic cells of a protein that catalyzes the dehydrogenation/isomerization of C21 and C19 steroids. Endocrinology 126:2493-2498
13. Mizokami A, Koh E, Fujita H, Maeda Y, Egawa M, Koshida K, Honma S, Keller ET, Namiki M 2004 The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer Res 64:765-771
14. Miyamoto H, Yeh S, Lardy H, Messing E, Chang C 1998 Delta5- androstenediol is a natural hormone with androgenic activity in human prostate cancer cells. Proc Natl Acad Sci USA 95:11083-11088
15. Tan J, Sharief Y, Hamil KG, Gregory CW, Zang DY, Sar M, Gumerlock PH, deVere White RW, Pretlow TG, Harris SE, Wilson EM, Mohler JL, French FS 1997 Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol 11:450-459
16. Wang Q, Li W, Liu XS, Carroll JS, Jänne OA, Keeton EK, Chinnaiyan AM, Pienta KJ, Brown M 2007 A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell 27:380-392
17. Takahashi M, Luu-The V, Labrie F 1990 Inhibitory effect of synthetic progestins, 4-MA and cyanoketone on human placental 3 β-hydroxysteroid dehydrogenase/5-4-ene-isomerase activity. J Steroid Biochem Mol Biol 37:231-236
18. Veldscholte J, Ris-Stalpers C, Kuiper GG, Jenster G, Berrevoets C, Claassen E, van Rooij HC, Trapman J, Brinkmann AO, Mulder E 1990 A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys ResCommun 173:534-540
19. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ 2008 Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 68:5469-5477
20. Attard G, Reid AH, A'Hern R, Parker C, Oommen NB, Folkerd E, Messiou C, Molife LR, Maier G, Thompson E, Olmos D, Sinha R, Lee G, Dowsett M, Kaye SB, Dearnaley D, Kheoh T, Molina A, de Bono JS 2009 Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 27:3742-3748